Loading clinical trials...
Loading clinical trials...
Combination Treatment of Polyethylene Glycol Thymosin alpha1 (PEG-Tα1) and Adefovir for Hepatitis B e Antigen (HBeAg) -Positive Chronic Hepatitis B: A Multi-center Randomized, Double-blind, Parallel-controlled Phase II Trial
Conditions
Interventions
PEG-Tα1
Placebo to match PEG-Tα1
+1 more
Locations
12
China
302 Military Hoapital of China
Beijing, Beijing Municipality, China
Hainan General Hospital
Haikou, Hainan, China
The Third Hospital of Hebei Medical University
Shijiazhuang, Hebei, China
The Second Xiangya Hospital of Central South University
Changsha, Hunan, China
81 Military Hospital of China
Nanjing, Jiangsu, China
Jiangsu Province Hospital
Nanjing, Jiangsu, China
Start Date
May 1, 2011
Primary Completion Date
June 1, 2013
Completion Date
August 1, 2013
Last Updated
February 19, 2015
NCT04166266
NCT06550622
NCT05922306
NCT05870969
NCT04856085
NCT04780204
Lead Sponsor
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions